RISC is a response-mode funding programme that was established to fund potentially paradigm-changing projects which proposed new and radical ideas for health research that could lead to a step change in the care and management of patients. Following a comprehensive review at the end of 2010, the Research for Innovation, Speculation and Creativity (RISC) programme is now closed and no further competitions will be held. Existing grants continue to be managed by the NIHR Central Commissioning Facility.
Awards
Awards were made to 19 speculative, novel proposals. Details of these projects can be viewed here. All existing grants continue to be managed by the Central Commissioning Facility (CCF).
RISC projects funded to date met with the following criteria by:
- Setting out a clearly stated hypothesis and approach, with particular attention to the research design and methodology;
- Describing the potential impact of the project;
- Containing a clear statement of objectives and a demonstration that the design of the project is appropriate to meet those objectives;
- Demonstrating an understanding of the risks that are being taken and prove that the work has not been undertaken elsewhere;
- Showing that current research governance frameworks and procedures for ethical approval have been followed;
- Giving a full justification for the duration of the project and financial support requested.
Awardees
All awardees are required to submit a final report. On completion of their research, award holders can apply to the Research for Patient Benefit programme to further develop the research theme if appropriate.
Reviewing and managing your RISC award
The CCF extranet previously used for the RISC programme is no longer available. Since the RISC programme is now closed to new submissions it will not be part of the new research management system. Any enquiries from existing award holders will need to be made through the relevant CCF Programme Manager.
- Managing your award: For award holders, please contact the programme manager for further details.